Go to the USUHS home page

  Our products
  A to Z index
  Contact us

Biodosimetry Tools

Emergency Response Resources
  Advisory team
  Other resources

Managing Radiation Casualties
  Depleted uranium
  Potassium iodide
  Prussian blue
  Radiation patient treatment
  Managing radiological casualties
  Response to nuclear detonation
      • 1st Edition (Jan 2009)
      • 2nd Edition (Jun 2010)
  NCRP recommendations
  Consequences of nuclear warfare

Medical Effects of Ionizing Radiation
  In-person course
  Online course
  Schedule, fees, registration
  Course resources
  » What is ionizing radiation? «
  » Veterans' radiation exposure «

Product Quick List
  Exposure assessment tools

  Books/book chapters
  Contract reports
  Journal articles/supplements
  Reports/report chapters
  Scientific reports
  Special publications
  Technical reports

Register AFRRI Products

Research Programs
  Combined Injury: Radiation with
      Other Insults

  Internal Contamination and
      Metal Toxicity

  Countermeasure Development

2014 AFRRI Seminars

USU Dept. of Radiation Biology
You are here:  HOME  >  What's New  >  Peer review validates AFRRI research of measuring radioprotection drug by liquid chromatography

New handbook guides
medical decisions in a
radiological emergency

Dept. of Homeland Security
medical experts visit AFRRI

Ceremony welcomes
new AFRRI director

Unprecedented growth marks
AFRRI director's tenure

NRC Commissioner
tours AFRRI

Special assignment:
The Vancouver Olympics

American Nuclear Society
unveils historic-landmark plaque

Historic landmark plaque
to be installed at defense lab

AFRRI receives historic
award from American
Nuclear Society

Iraq researchers
tour AFRRI

AFRRI awarded nuclear
historic landmark status

AFRRI leaders, other research
reactor experts convene
at annual conference

Research pioneer
touched lives, influenced
future of radiation science

Former AFRRI
scientific director was
pioneer in radiation research

Researchers share latest
radiation-effects findings
with military medical community

AFRRI scientific director
elected to NCRP

Scientists deliberate
on diagnostics for
partial-body irradiation

New software to aid
treatment decisions during
radiation exposure incidents

International experts on
radiation exposure assessment
to convene at AFRRI

Ceremony marks change
of director at AFRRI

FDA clears 5-AED for
human clinical studies

New collaboration
will develop radiation

Training for the unthinkable

AFRRI employees participate
in MASCAL drill

EPA awards AFRRI scientists
with highest honor

DoD commends AFRRI
for response to terrorism

Ceremony welcomes
new AFRRI director

Revised handbook expands
casualty management

Peer review validates
AFRRI research of
measuring radioprotection
by liquid chromatography

MEIR course available
on handy card-size disc

AFRRI launches software
for radiation casualty

Chernobyl liquidators'
teeth may link radiation
dose and disease

Individual exposure
takes heat in
radiation study

Russian scientists take
different path in search
for radioprotectors

Peer review validates AFRRI research of measuring radioprotection drug by liquid chromatography

BETHESDA, Md., Jan. 24, 2003—AFRRI researchers have validated a method of measuring WR1065—the active, radioprotective drug derived from the metabolism of amifostine—and WR-33278, its derivative symmetrical disulfide, in the blood by liquid chromatography with electrochemical detection (LC-ECD). Another independent researcher validated the method.

The AFRRI research team—James A. Pendergrass Jr., Venkataraman Srinivasan, K. Sree Kumar, William E. Jackson III, and Thomas M. Seed—used WR-2721 in a biodegradable, slow-release pellet designed for injection under the skin in laboratory mice. They studied whether the radioprotection of WR-2721 in mice correlates with the levels of WR-1065 found in the blood but, they wrote in their research paper, they needed "a reliable and sensitive method of analysis" to detect these compounds.

"Although WR-2721 is an excellent radioprotective drug," the researchers wrote in the Journal of AOAC International (vol. 85, No. 3, 2002, pages 551-554), "its use is limited because of toxicity. One approach to limiting toxicity is to slow down its release into the bloodstream."

Several laboratories use LC-ECD to measure WR-1065 and WR-33278, but the AFRRI research team was unable consistently to repeat in its laboratory the results reported in the literature. "We just weren't able to reproduce what some of those labs reported in the literature," Mr. Pendergrass said.

However, "I found a published report where a lab added cysteamine to their mobile phase and, voilà, I tried it and got reproducible results. Because I had tried so many methods and failed until I hit upon the current one, I wanted to publish a report that proved that my method was independently reproducible using similar equipment and the same mobile phase."

In the reported AFRRI experiments, "the measurements were repeatable day after day, and the accuracy and precision of each day's measurements were very acceptable," Mr. Pendergrass said. After he and his colleagues developed a method that was consistently reproducible, they then sought to show that another laboratory could duplicate their method.

The AFRRI researchers asked Dr. Wayne A. Kleinman of the American Health Foundation in Valhalla, NY, to reproduce their experiment, and he duplicated the thiol and disulfide measurements with similar accuracy and precision.